年間 6 号発行
ISSN 印刷: 1045-4403
ISSN オンライン: 2162-6502
IF:
1.6
5-Year IF:
2.2
Immediacy Index:
0.3
Eigenfactor:
0.00058
JCI:
0.33
SJR:
0.345
SNIP:
0.46
CiteScore™::
2.5
H-Index:
67
Indexed in
CRISPR-CAS Replacing Antiviral Drugs against HIV: An Update
Get access
要約
Various antiretroviral drugs do not kill or cure the human immunodeficiency virus (HIV) but do prevent the replication of the virus. The combination of antiretroviral drugs is known as highly active antiretroviral therapy (HAART). Current drug therapies effectively suppress HIV-1 replication but do not inactivate the provirus that persists in latent reservoirs. Guide RNA (gRNA)-directed CRISPR/Cas9 system can be used for sequence-specific attacks on this proviral DNA. The biggest achievement might be the complete elimination of HIV from infected cells. A study revealed that the tail injection, in transgenic mice and rats having HIV-1 genome, of an adenoassociated virus (AAV) vector expressing a short version of the Cas9 endonuclease (saCas9) and the gRNAs resulted in the cleavage of integrated HIV-1 DNA and excision of a DNA fragment spanning between the LTR and Gag gene in the spleen, liver, heart, kidney, and circulating lymphocytes. HIV-1 has capacity to escape the attack on its genome from most of inhibitors. Thus, to achieve successful antiretroviral treatment, combinations of several antiviral therapies have been applied that are based on two important facts. The first is that multiple drugs lead to synergistic or additive inhibition, and the second is that the combinational therapy increases chances of drug resistance. The success that has been achieved with the help of the genetically engineered tool CRISPR is that dCas9 protein alone can efficiently silence viral gene expression in bacteria with sgRNA. All the reported investigations have indicated that CRISPR/Cas9 can be used as immune machinery into human cells in the form of novel antivirus tools.
-
HIV.gov [Internet]. HIV treatment overview. United States: U.S. Department of Health and Human Services, Inc.; c2018. Available from: https://www.hiv.gov/hiv-basics/staying-in-hiv-care/hiv-treatment/hiv-treatment-overview.
-
IAPAC. Fact sheet 403: what is antiretroviral therapy 16. (ART)? Pennsylvania: International Association of Providers of AIDS Care, Inc.; c2014. Available from: http://www.aidsinfonet.org/fact_sheets/view/403.
-
Myher J, Sifris D. Antiretrovirals overview. How combi-nation therapy renders HIV powerless. New York: Very Well Health, Inc.; 2017. Available from https://www.verywellhealth.com/what-are-antiretrovirals-and-how-do-they-work-49639.
-
Palmisano L, Vella S. A brief history of antiretroviral therapy of HIV infection: success and challenges. Annali dell'Istituto Superiore SanitA. 2011;47:44-8.
-
Liao HK, Gu Y, Diaz A, Marlett J, Takahashi Y, Li M, Suzuki K, Xu R, Hishida T, Chang CJ, Esteban CR. Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells. Nature Commun. 2015 Mar 10;6:6413.
-
Liao HK, Li M, Martinez LM, Belmonte JC. Stem cell, CRISPR and HIV. Cell Cycle. 2015 Jul 3;14(13):1991.
-
McGarty TP. Crisprs and cancer. Technical report: 21. TWP.111; 2014. doi: 10.13140/2.1.1431.1205.
-
Du D, Qi LS. An introduction to CRISPR technology for genome activation and repression in mammalian cells. Cold Spring Harbor Protocols. 2016 Jan 1;2016(1).
-
Kabadi AM, Gersbach CA. Engineering synthetic TALE 22. and CRISPR/Cas9 transcription factors for regulating gene expression. Methods. 2014 Sep 30;69(2):188-97.
-
Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, Lim WA. CRISPR-mediated modular RNA-23. guided regulation of transcription in eukaryotes. Cell. 2013 Jul 18;154(2):442-51.
-
Gilbert LA, Horlbeck MA, Adamson B, Villalta JE, Chen Y, Whitehead EH, Guimaraes C, Panning B, Ploegh HL, Bassik MC, Qi LS. Genome-scale CRISPR-mediated control of gene repression and activation. Cell. 2014 Oct 23;159(3):647-61.
-
Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene ex-pression. Cell. 2013 Feb 28;152(5):1173-83.
-
Tanenbaum ME, Gilbert LA, Qi LS, Weissman JS, Vale RD. A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell. 2014 Oct 23;159(3):635-46.
-
Zalatan JG, Lee ME, Almeida R, Gilbert LA, Whitehead 27. EH, La Russa M, Tsai JC, Weissman JS, Dueber JE, Qi LS, Lim WA. Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell. 2015 Jan 15;160(1-2):339-50.
-
Hou Z, Zhang Y, Propson NE, Howden SE, Chu LF, Sontheimer EJ, Thomson JA. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci USA. 2013 Sep 24;110(39):15644-9.
-
Gonjalves A, Gonjalves FF. CRISPR-Cas9 gene editing permanently eliminates HIV-1 DNA. J Hum Virol Retroviral. 2017;5(6):00177.
-
Feelixge HS, Stone D, Pietz HL, Roychoudhury P, Greninger AL, Schiffer JT, Aubert M, Jerome KR. Detection of treatment-resistant infectious HIV after genome-directed antiviral endonuclease therapy. Antiviral Res. 2016 Feb 1;126:90-8.
-
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protocols. 2013 Nov;8(11):2281. Ter Brake O, Konstantinova P, Ceylan M, Berkhout B. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther. 2006 Dec 1;14(6):883-92.
-
Cheng AW, Wang H, Yang H, Shi L, Katz Y, Theunissen TW, Rangarajan S, Shivalila CS, Dadon DB, Jaenisch R. Multiplexed activation of endogenous genes by CRIS-PR-on, an RNA-guided transcriptional activator system. Cell Res. 2013 0ct;23(10):1163.
-
Chavez A, Scheiman J, Vora S, Pruitt BW, Tuttle M, Iyer EP, Lin S, Kiani S, Guzman CD, Wiegand DJ, Ter-Ovanesyan D. Highly efficient Cas9-mediated transcriptional programming. Nature Methods. 2015 Apr; 12(4):326.
-
Konermann S, Brigham MD, Trevino AE, Joung J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS, Nishimasu H, Nureki O. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2015 Jan;517(7536):583.
-
Yin L, Hu S, Mei S, Sun H, Xu F, Li J, Zhu W, Liu X, Zhao F, Zhang D, Cen S. CRISPR/Cas9 Inhibits multiple steps of HIV-1 infection. Human Gene Ther. 2018 Nov 1;29(11):1264-76.
-
Kind T. CRISPR/Cas9 for advanced DNA and RNA editing. Davis, CA: West Coast Metabolomics Center, UC Davis Genome Center; 2015.
-
Kaminski R, Chen Y, Fischer T, Tedaldi E, Napoli A, Zhang Y, Karn J, Hu W, Khalili K. Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing. Sci Rep. 2016 Mar 4;6:22555.
-
Dampier W, Sullivan NT, Mell J, Pirrone V, Ehrlich G, Chung CH, Allen AG, DeSimone M, Zhong W, Kercher K, Passic S. Broad spectrum and personalized gRNAs for CRISPR/Cas9 HIV-1 therapeutics. AIDS Res Human Retroviruses. 2018 Nov 1;34(11):950-60.
-
Gendelman H, Dash P, Edagwa B, Gorantla S, Kaminski R, Bella R, Young WB, Khalili K. D-110 Synergism between Crispr/cas9 and Laser Art leads to elimination of Hiv-1 with no rebound in humanized mice. J Acquir Immune Defic Syndr. 2018 Apr 1;77:42.
-
Foley KM. Chinese scientists used Crispr gene editing on human patients. Philadelphia, PA: University of Pennsylvania; 2018. Available from: https://qz.com/1185488/chinese-scientists-used-crispr-gene-editing-on-86-human-patients/.
-
Wang G, Zhao N, Berkhout B, Das AT. A combinatorial CRISPR-Cas9 attack on HIV-1 DNA extinguishes all infectious provirus in infected T cell cultures. Cell Rep. 2016 Dec 13;17(11):2819-26.
-
Horizon Inspired Cell Solutions. CRISPR-Cas9 Gene Editing Applications. Horizon; c2018. Available from: https://horizondiscovery.com/en/applications/crispr-cas9/crispr-cas9-gene-editing-applications.
-
Macchione Micaela A., Aristizabal Bedoya Dariana, Figueroa Francisco N., Muñoz-Fernández María Ángeles, Strumia Miriam C., Nanosystems Applied to HIV Infection: Prevention and Treatments, International Journal of Molecular Sciences, 21, 22, 2020. Crossref
-
Pluta Aneta, Jaworski Juan P., Cortés-Rubio César N., Balance between Retroviral Latency and Transcription: Based on HIV Model, Pathogens, 10, 1, 2020. Crossref
-
Kayesh Mohammad Enamul Hoque, Amako Yutaka, Hashem Md Abul, Murakami Shuko, Ogawa Shintaro, Yamamoto Naoki, Hifumi Tatsuro, Miyoshi Noriaki, Sugiyama Masaya, Tanaka Yasuhito, Mizokami Masashi, Kohara Michinori, Tsukiyama-Kohara Kyoko, Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA, Virus Research, 290, 2020. Crossref
-
Chen Chao, Hu Xiaodong, Wang Chunxi, Lan Wenxian, Wu Xiaoyu, Cao Chunyang, Structure- and Mechanism-Based Research Progress of Anti-acquired Immune Deficiency Syndrome Drugs, Chinese Journal of Organic Chemistry, 41, 8, 2021. Crossref
-
Wang Qun, Su Qi, Liu Bowen, Li Yan, Sun Wanli, Liu Yanxue, Xue Ruyu, Chang Shuang, Wang Yixin, Zhao Peng, Enhanced Antiviral Ability by a Combination of Zidovudine and Short Hairpin RNA Targeting Avian Leukosis Virus, Frontiers in Microbiology, 12, 2022. Crossref
-
Saudagar Neetu R., Boraste Sahebrao S., Shinkar Dattatray M., Pingale Prashant L., Amrutkar Sunil V., Gene-Specific Drug Delivery System: An Art of War, Biosciences Biotechnology Research Asia, 19, 2, 2022. Crossref